Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. - Wikidata - wikimedia - TriplyDB

Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.

Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.

http://www.wikidata.org/entity/Q47812640

about

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia.Evidence of canonical somatic hypermutation in hairy cell leukemia Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia.LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia.Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia.CD38 and chronic lymphocytic leukemia: a decade later.Prognostic factors in CLL Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia.Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia.Recent advances in bone marrow biopsy pathology.Detection methods of ZAP-70 in chronic lymphocytic leukemia.Surface profiles for subclassification of chronic lymphocytic leukemia.Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia.CD1d expression as a prognostic marker for chronic lymphocytic leukemia.Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia.Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study.High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications.External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia.A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients.Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study.A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: A retrospective multicentric GIMEMA experience

P2860

Q34166551-A859A25F-2CC2-467F-9E09-6F051E823520 Q34978154-85AD9382-C7ED-4A7F-8AAF-36DAB4097172 Q35001615-33A7334F-79ED-4644-ADC8-8FABA81D1213 Q35140580-FF3561E1-19E7-4CE3-89AF-F64F2970A2BB Q35143479-A148C8FC-9004-47A5-B6E8-FDC37928C859 Q35192691-DD7402FB-4AC5-4E45-ADA2-526ADF36F71B Q36615126-36DF48E0-D1A0-46AE-854A-837BEE382A55 Q36852233-FCBF1DEE-BBFA-4522-8303-0068223BF9B7 Q36925185-0ABCA009-D8F7-4231-B699-DA5DCAA6C636 Q37179155-58036005-DE30-483D-9C16-0571A02991E7 Q37397734-252865B9-2E04-4702-A5D7-FBEB15E2C4D9 Q37892409-F4411881-652B-40F5-AF3E-55C4A006CF8E Q37948956-5F1368C8-CEEE-4445-BF04-EAC999B9B10F Q38680890-785DD9BE-1551-407D-8327-A4F701250FF8 Q38822886-4332F12D-35D2-44C4-BB1F-C1A87FAD678C Q41092333-C8DF9CD7-C8E4-4292-9982-5E0A25ACAEDA Q44020427-EB818955-9509-48E6-8434-084FAFF6E932 Q44447816-6DA7DB03-AE34-4DCB-BD90-55F01E82158E Q45181930-085E98CF-CBD5-4697-910E-493B312C490F Q46444068-CC559F5C-9B8C-4868-A807-7A92C5508711 Q50889970-2C1C3015-934B-439F-93D4-D258845ACE34 Q52897018-1E72F3DD-1C01-4779-95BC-4355D606F61F Q54323411-7AD2C0C6-39BD-4E41-8539-E170CE081807 Q57279275-BC7FB8B5-8732-45A5-B035-4067AA99986B Q58000962-CB872809-FE6C-4163-B22E-44BE3EE2B036

P2860

Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.

http://www.wikidata.org/entity/Q47812640

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Definition of progression risk ...... chronic lymphocytic leukaemia.

@en

Definition of progression risk ...... chronic lymphocytic leukaemia.

@nl

type

label

Definition of progression risk ...... chronic lymphocytic leukaemia.

@en

Definition of progression risk ...... chronic lymphocytic leukaemia.

@nl

prefLabel

Definition of progression risk ...... chronic lymphocytic leukaemia.

@en

Definition of progression risk ...... chronic lymphocytic leukaemia.

@nl

P1433

Q47812640-8E3AEF1D-AB08-4AF1-9422-47238B915753

P1476

Q47812640-C6952110-6270-4AEA-B41F-4CB50E9F3626

P2093

Q47812640-10AB84E2-8F99-4AB8-B7A1-609DD1AFA719

Q47812640-3AB1F108-6F23-4BE5-9CCE-107530B6231C

Q47812640-45A47AC2-2853-499F-BC64-DDAB8E937AFB

Q47812640-4CE6751B-EDD6-40DC-A16B-55CDBEB5C727

Q47812640-56D4B2E1-B956-4F3F-8F0F-5851ABE2C956

Q47812640-7D300DEB-6B4F-4A51-B7D1-B330C828B7DE

Q47812640-81E99338-279C-4C32-A0B4-2295B00B8A69

Q47812640-9234F6AD-E506-4301-A62C-231DF8FBEB7D

Q47812640-92981A53-BC56-4F1D-8616-29809B06817C

Q47812640-B38C74B1-7D9B-4D2F-975A-E77C0031C710

P304

Q47812640-C46536B2-98AF-43B6-A56D-476D04DF54F9

P31

Q47812640-E78C1CFA-986D-47EE-852B-24144B9277E2

P356

Q47812640-97C2CAC8-4E32-417E-B4A9-80D21EF214F0

P407

Q47812640-ADCE6986-D8A2-43BB-991E-8CE109BA6C37

P433

Q47812640-CDAC3B12-467C-4554-8555-3D7CD1116E05

P478

Q47812640-A7F0C121-BE72-408B-9515-E7AEDAD36D6A

P50

Q47812640-040D94F7-EA8F-412F-9513-9C596357F3B8

Q47812640-BFF88D37-A974-49BC-A6A7-05E0FBAC0EB8

Q47812640-D5199E9A-5153-456C-97FA-FFFF6594EFA5

Q47812640-DF318C81-6EFA-4B1E-9EDD-21871E865598

Q47812640-E4D22C1C-2DA3-45F5-AC37-06AA1FC3ED65

P577

Q47812640-65BFFDFF-7936-400D-ADF5-EEC1CD1CF91E

P5875

Q47812640-A209CE04-51D2-4102-A196-4F66369CC232

P698

Q47812640-F769B2D7-F49E-4921-B995-ED28069E6F75

P921

Q47812640-F068809F-8F3A-49F0-B401-65CEF089772D

P356

J.1365-2141.2009.07703.X

P1433

British Journal of Haematology

P1476

Definition of progression risk ...... chronic lymphocytic leukaemia.

@en

P2093

Carla Mazzone

http://www.w3.org/2001/XMLSchema#string

Claudia Sonaglio

http://www.w3.org/2001/XMLSchema#string

Daniele Reverberi

http://www.w3.org/2001/XMLSchema#string

Edoardo Rossi

http://www.w3.org/2001/XMLSchema#string

Eugenio Lucia

http://www.w3.org/2001/XMLSchema#string

Fortunato Morabito

http://www.w3.org/2001/XMLSchema#string

Gianluca Festini

http://www.w3.org/2001/XMLSchema#string

Massimo Gentile

http://www.w3.org/2001/XMLSchema#string

Mauro Megna

http://www.w3.org/2001/XMLSchema#string

Mauro Spriano

http://www.w3.org/2001/XMLSchema#string

P304

44-53

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2009.07703.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

146

http://www.w3.org/2001/XMLSchema#string

P50

Manlio Ferrarini

Giovanna Cutrona

P577

2009-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24423741

http://www.w3.org/2001/XMLSchema#string

P698

19438486

http://www.w3.org/2001/XMLSchema#string

P921